Abbott Laboratories reports results for the quarter ended September 30 - Earnings Summary

• Abbott Laboratories ABT.N reported quarterly adjusted earnings of $1.42​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $1.30. The mean expectation of twenty six analysts for the quarter was for earnings of $1.42 per share. Wall Street expected results to range from $1.31 to $1.44 per share.

• Revenue rose 14.5% to $13.01 billion from a year ago; analysts expected $13.00 billion.

• Abbott Laboratories's reported EPS for the quarter was 53 cents​.

• The company reported quarterly net income of $920 million.

• Abbott Laboratories shares had risen by 3.7% this quarter and lost 18.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for Abbott Laboratories is $120.50, about 15% above its last closing price of $102.45

This summary was machine generated from LSEG data October 21 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)